Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
Aimovig (1) ·
Ajovy (1) ·
Auvelity (dextromethorphan/bupropion ER) (1) ·
Belsomra (1) ·
Caplyta (1) ·
Dayvigo (1) ·
Emgality (1) ·
Quviviq (1) ·
REL-1017 / esmethadone (investigational; not yet FDA-approved as of mid-2024) (1) ·
Rexulti (1) ·
Sunosi (1) ·
Trintellix (US), Brintellix (formerly) (1) ·
Viibryd (1) ·
Vraylar (1) ·
Vyepti (1) ·
Zavzpret (zavegepant) (1) ·
Zurzuvae (1)
classes:
5HT1A activity than aripiprazole (1) ·
5HT2A (1) ·
5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity (1) ·
Anti-CGRP ligand monoclonal antibody (3) ·
Anti-CGRP receptor monoclonal antibody (1) ·
Atypical antipsychotic (3) ·
CGRP receptor antagonist (1) ·
D2/5HT1A partial agonist with stronger α1A (1) ·
D2/D3/5HT1A partial agonist (1) ·
Dual orexin receptor antagonist (DORA) (3) ·
GABA-A positive allosteric modulator (oral) (1) ·
Gepant (1) ·
low-trapping) (1) ·
Multimodal antidepressant: SERT inhibitor + 5HT1A agonist + 5HT1B partial agonist + 5HT3/5HT7 antagonist (1) ·
Neuroactive steroid (1) ·
NMDA receptor antagonist (uncompetitive (1) ·
NMDA receptor antagonist + sigma-1 agonist + NDRI (combination) (1) ·
Norepinephrine-dopamine reuptake inhibitor (NDRI) (1) ·
Serotonin partial agonist reuptake inhibitor (SPARI) (1) ·
the first approved (1) ·
wake-promoting agent (1)
mechanism:
None (7) ·
Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) ·
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) ·
Small-molecule CGRP receptor antagonist; intranasal formulation (1) ·
Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes. (1)
uses:
Acute treatment of migraine with or without aura in adults (1) ·
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) ·
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) ·
Investigational for major depressive disorder; trials underway (phase 3 mixed results) (1) ·
Major depressive disorder in adults (FDA-approved 2011) (1) ·
Major depressive disorder in adults (FDA-approved 2013). Notable for evidence of cognitive benefit (processing speed) that distinguishes it from other antidepressants. (1) ·
Major depressive disorder in adults (FDA-approved August 2022) (1) ·
Postpartum depression (PPD) in adults (FDA-approved 2023) (1) ·
Preventive treatment of migraine in adults (1) ·
Preventive treatment of migraine in adults (episodic and chronic) (2) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1)
starting dose:
1 tablet (dextromethorphan 45 mg / bupropion 105 mg) PO daily × 3 days, then increase to 1 tablet BID (1) ·
10 mg (one spray) intranasally in one nostril (1) ·
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food) (1) ·
10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed (1) ·
100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) ·
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) ·
42 mg PO once daily with food (no titration) (1) ·
5 mg PO at bedtime; may increase to 10 mg if inadequate (1) ·
50 mg PO once daily with fatty food in the evening × 14 days (1) ·
70 mg SC monthly; may increase to 140 mg monthly (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) ·
Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1) ·
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) ·
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1) ·
Trials use 25 mg or 50 mg PO daily (1)
preparations:
0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) ·
1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) ·
10 mg, 20 mg, 40 mg tablets (1) ·
10 mg/spray nasal solution (1) ·
100 mg/mL vial for IV infusion (1) ·
120 mg/mL prefilled syringe or autoinjector (1) ·
20 mg, 25 mg, 30 mg capsules (1) ·
225 mg/1.5 mL prefilled syringe or autoinjector (1) ·
25 mg, 50 mg tablets (1) ·
42 mg capsules (1) ·
5 mg, 10 mg tablets (1) ·
5 mg, 10 mg, 15 mg, 20 mg tablets (1) ·
5 mg, 10 mg, 20 mg tablets (1) ·
70 mg/mL or 140 mg/mL prefilled autoinjector (1) ·
75 mg, 150 mg tablets (1) ·
Dextromethorphan 45 mg + bupropion 105 mg ER tablets (1) ·
Investigational oral capsule (1)
fda max:
10 mg per 24 h (1) ·
10 mg/d (1) ·
140 mg/month (1) ·
150 mg/d (1) ·
2 tablets/day (dextromethorphan 90 mg / bupropion 210 mg) (1) ·
20 mg/d (2) ·
240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) ·
300 mg/quarter (1) ·
4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) ·
40 mg/d (1) ·
42 mg/d (1) ·
50 mg/d (1) ·
50 mg/d × 14 d (1) ·
6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1) ·
675 mg/quarter (1) ·
Not yet approved (1)
routes:
onset:
4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism) (1) ·
Antipsychotic effect over weeks (1) ·
Day 3 of dosing in trials; sustained through day 45 (1) ·
Effect demonstrated within 24 hours in some patients (1) ·
Onset of preventive effect over weeks; some patients respond after first dose (1) ·
Over weeks (2) ·
Pain relief reported within 15 min in trials (1) ·
Rapid (within 1 week in trials) (1) ·
Significant antidepressant response by week 1 in trials (faster than monoaminergic antidepressants which take 4-6 weeks) (1) ·
Typical antidepressant 4-6 week onset (1) ·
Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) ·
Weeks for psychosis/mood efficacy (1) ·
~30 min (3) ·
~30-60 min (1)
duration:
14-day course; effect persists after discontinuation in trials (1) ·
3-month dosing interval (1) ·
Daily dosing (5) ·
Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1) ·
Monthly dosing (2) ·
Monthly or quarterly dosing (1) ·
Sustained with twice-daily dosing (1) ·
~48 h sustained pain freedom in responders (1) ·
~7-8 hours (3) ·
~9 hours (1)
halflife:
Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) ·
Dextromethorphan ~22 h (when CYP2D6 inhibited); bupropion ~21 h (1) ·
Not formally established (1) ·
~12 hours (1) ·
~16-23 hours (1) ·
~17-19 hours (longer than daridorexant) (1) ·
~18 hours (terminal) (1) ·
~25 hours (1) ·
~27 days (2) ·
~28 days (1) ·
~31 days (1) ·
~6.6 h (1) ·
~66 hours (1) ·
~7.1 hours (1) ·
~8 hours (shorter than suvorexant and lemborexant) (1) ·
~91 hours (1)
bioavailability:
100% (IV) (1) ·
Adequate (food-dependent, must take with fatty meal) (1) ·
Adequate oral bioavailability (1) ·
Limited but adequate; take with food (1) ·
Not formally characterized for the combination (1) ·
Not formally established (1) ·
Not formally established (high SC) (1) ·
Oral bioavailability suitable for daily dosing (1) ·
~44% (1) ·
~5% intranasal (1) ·
~62% (1) ·
~72% (with food); much lower fasting (~36%) (1) ·
~75% (1) ·
~82% (1) ·
~82% SC (1) ·
~95% (2)
pregnancy:
Investigational (1) ·
Limited data (1) ·
Limited data; avoid (9) ·
Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) ·
Limited data; National Pregnancy Registry available (1) ·
Limited data; National Pregnancy Registry for Atypical Antipsychotics (1) ·
Limited data; pregnancy exposure registry available (1) ·
Limited data; weigh benefits/risks (2)
legal: (Click arrow to add another value)
Showing below up to 17 results in range #1 to #17.